Information Technology Project Coordinator IT Project Coordinator Location: Watford (Hybrid 3 days office based and 2 days working from home) Salary: Competitive + Benefits Closing date: 31st July 2026 About Us At Corona Energy, we are proud to
Information Technology Developer IT Developer Location: Watford (Hybrid 3 days office based and 2 days working from home) Salary: Competitive + Benefits Closing date: 31st July 2026 About Us At Corona Energy, we are proud to be one
Information Technology Service Delivery Manager IT Service Delivery Manager Location: Watford (Hybrid 3 days office based and 2 days working from home) Salary: Competitive + Benefits Closing date: 31st July 2026 About Us At Corona Energy, we are
ICT User Support Engineer - Cambourne Salary: *GBP*35,412 per annum rising to *GBP*38,220 per annumBasis: Full timePackage: 37 hours per week, Hybrid Working, Flexitime scheme, Local Government Pension Scheme (LGPS), Holiday allowance of 25 days (plus
Performance & Insight Engineer - Kempston Salary: *GBP*45,091 per annum - *GBP*49,282 per annumBasis: Full timePackage: 37 Hours Per Week, Hybrid Working, Flexitime Scheme, Local Government Pension Scheme, Holiday allowance of 25 days (plus public holidays)
Digital and AI Officer - Kempston Salary: *GBP*32,061 per annum rising to *GBP*34,434 per annumBasis: Full timePackage: 37 Hours Per Week, Hybrid Working, Flexitime Scheme, Local Government Pension Scheme, Holiday allowance of 25 days (plus public
Business Administration - Personal Support - Reading, Berkshire,RG7 4PR Job Type:Full-TimeSalary: Additional Benefits Business Administrator - Personal Assistant Location: RG7 4PR , located between Reading and Basingstoke, with free onsite parking . Package: Up to 40,000
HGV Vehicle Technician - Reading, Berkshire,RG7 4PR Job Type:Full-TimeSalary: 40000 - 45000 per annum + Pension Role title: HGV Vehicle Technician Closing date: 30th July 2026 Location: RG7 4PR , located between Reading and Basingstoke, with
Scientist - Infectious Diseases - Oxford Immunocore (NASDAQ: IMCR) is a pioneering, commercial-stage T cell receptor biotechnology company whose purpose is to develop and commercialize a new generation of transformative medicines which address unmet patient needs